New panel of microsatellite alterations detectable in the EBC for lung cancer prognosis

Our research group demonstrated, in a precedent study, the prognostic power of the 3p microsatellites alterations (MAs) detectable in exhaled breath condensate (EBC) in NSCLC patients. The analysis of genetic markers in the EBC might have precious clinical and economic consequences when inserted in diagnostic and follow up programs for lung cancer. The aim of this study was to evaluate the prognostic value of a new panel of MAs in the EBC of patients with NSCLC. We enrolled 45 NSCLC patients during a period of 36 months and the follow-up period was 156 weeks. We analyzed MAs for eight markers in EBC samples: D3S2338, D3S1266, D3S1300, D3S1304, D3S1289, D5S2094, D3S1313, and AFMa305ye1. Our study showed that the presence of more than 2 simultaneous MAs reduces outcome in NSCLC patients. The new panel of eight microsatellites markers proposed in EBC samples could have a potential clinical role in assessing survival in lung cancer patients.

[1]  Long Tian,et al.  Microsatellite alteration in multiple primary lung cancer. , 2014, Journal of thoracic disease.

[2]  S. Jang,et al.  Comparison of genetic and epigenetic alterations at 11 tumor suppressor loci in pulmonary sclerosing hemangioma and adenocarcinoma , 2011, Experimental lung research.

[3]  G. E. Carpagnano,et al.  Exhaled ERCC-1 and ERCC-2 microsatellite alterations in NSCLC patients. , 2010, Lung cancer.

[4]  A. Spanevello,et al.  Prognostic value of exhaled microsatellite alterations at 3p in NSCLC patients. , 2009, Lung cancer.

[5]  E. Brambilla,et al.  Fragile histidine triad gene inactivation in lung cancer: the European Early Lung Cancer project. , 2009, American journal of respiratory and critical care medicine.

[6]  L. Crinò,et al.  Plasma DNA, Microsatellite Alterations, and p53 Tumor Mutations Are Associated with Disease-Free Survival in Radically Resected Non-small Cell Lung Cancer Patients: A Study of the Perugia Multidisciplinary Team for Thoracic Oncology , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[7]  A. Paradiso,et al.  3p microsatellite signature in exhaled breath condensate and tumor tissue of patients with lung cancer. , 2008, American journal of respiratory and critical care medicine.

[8]  Yuh-Shan Jou,et al.  Genomewide loss of heterozygosity and its clinical associations in non small cell lung cancer , 2005, International journal of cancer.

[9]  A. Paradiso,et al.  3p microsatellite alterations in exhaled breath condensate from patients with non-small cell lung cancer. , 2005, American journal of respiratory and critical care medicine.

[10]  F. Khuri,et al.  Prognostic implication of microsatellite alteration profiles in early-stage non-small cell lung cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[11]  P. Macdonald.  Waiting to exhale. , 1998, Nursing Times.

[12]  P. Zimmerman,et al.  Tumor progression and loss of heterozygosity at 5q and 18q in non-small cell lung cancer. , 1995, Cancer research.

[13]  P. Zimmerman,et al.  Correlation of loss of heterozygosity at 11 p with tumour progression and survival in non‐small cell lung cancer , 1994, Genes, chromosomes & cancer.